Suppliers and packagers for IBUPROFEN AND DIPHENHYDRAMINE CITRATE

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	IBUPROFEN AND DIPHENHYDRAMINE CITRATE	diphenhydramine citrate; ibuprofen	TABLET;ORAL	216204	ANDA	Better Living Brands, LLC	21130-228-12	1 BOTTLE in 1 CARTON (21130-228-12) / 40 TABLET, COATED in 1 BOTTLE	2023-11-15
Aurobindo Pharma	IBUPROFEN AND DIPHENHYDRAMINE CITRATE	diphenhydramine citrate; ibuprofen	TABLET;ORAL	216204	ANDA	Better Living Brands, LLC	21130-228-18	1 BOTTLE in 1 CARTON (21130-228-18) / 80 TABLET, COATED in 1 BOTTLE	2023-11-15
Aurobindo Pharma	IBUPROFEN AND DIPHENHYDRAMINE CITRATE	diphenhydramine citrate; ibuprofen	TABLET;ORAL	216204	ANDA	Better Living Brands, LLC	21130-228-23	1 BOTTLE in 1 CARTON (21130-228-23) / 120 TABLET, COATED in 1 BOTTLE	2023-11-15
Aurobindo Pharma	IBUPROFEN AND DIPHENHYDRAMINE CITRATE	diphenhydramine citrate; ibuprofen	TABLET;ORAL	216204	ANDA	Better Living Brands, LLC	21130-228-73	1 BOTTLE in 1 CARTON (21130-228-73) / 20 TABLET, COATED in 1 BOTTLE	2023-11-15

Supplier Landscape for Ibuprofen and Diphenhydramine Citrate

Last updated: February 19, 2026

This analysis identifies key suppliers for Ibuprofen and Diphenhydramine Citrate, critical active pharmaceutical ingredients (APIs). It details their manufacturing capabilities, regulatory compliance, and geographical presence, providing a foundation for supply chain risk assessment and strategic sourcing.

What are the Primary Manufacturers of Ibuprofen API?

Global production of Ibuprofen API is concentrated among a limited number of manufacturers with significant capacity and established regulatory track records. Key players include both integrated pharmaceutical companies and specialized API producers.

• BASF SE: A major chemical company with a dedicated pharmaceutical division, BASF produces Ibuprofen API at its facilities. The company emphasizes quality control and adherence to Good Manufacturing Practices (GMP).

  • Manufacturing Sites: Geographically diverse sites, including Germany and the United States, contribute to supply chain resilience.
  • Regulatory Approvals: Products are registered with major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • Capacity: While specific tonnage is proprietary, BASF's scale as a global chemical producer indicates substantial Ibuprofen API output.

• SI Group: This global developer and manufacturer of performance additives, process solutions, chemical intermediates, and pharmaceutical ingredients is a significant producer of Ibuprofen.

  • Key Facilities: Operates manufacturing plants in the United States and Europe.
  • Quality Standards: Adheres to ICH Q7 GMP guidelines.
  • Market Position: SI Group is recognized for its consistent supply and quality in the Ibuprofen market.

• Granules India Limited: An Indian pharmaceutical company that has established itself as a leading global supplier of APIs, including Ibuprofen.

  • Production Capacity: Operates multiple API manufacturing facilities in India, with significant dedicated Ibuprofen capacity. The company has publicly stated its position as one of the largest Ibuprofen manufacturers globally.
  • Regulatory Compliance: Holds accreditations from the FDA, EMA, and other international regulatory agencies. Its facilities undergo regular inspections.
  • Market Share: Granules India is frequently cited as a top-tier supplier, contributing a substantial percentage of the global Ibuprofen supply.

• IOL Chemicals and Pharmaceuticals Ltd. (IOLCP): Another prominent Indian API manufacturer with a substantial position in the Ibuprofen market.

  • Integrated Manufacturing: IOLCP operates backward integrated manufacturing for Ibuprofen, controlling key starting materials. This provides cost advantages and supply chain security.
  • Scale of Production: The company has consistently increased its Ibuprofen production capacity, positioning itself as one of the world's largest single-location producers.
  • Global Reach: Exports to over 80 countries, with regulatory approvals in numerous key markets.

• Other Notable Suppliers: Several other companies, including Shouguang RARX Pharma Co., Ltd. (China) and Hebei Jiheng Pharmaceutical Co., Ltd. (China), also contribute to the global Ibuprofen API supply chain. These suppliers are often characterized by high-volume production, catering to a broad customer base.

What are the Primary Manufacturers of Diphenhydramine Citrate API?

The production of Diphenhydramine Citrate API is also concentrated among specialized manufacturers, often with a focus on antihistamines and related compounds. Regulatory compliance and quality control are paramount due to its widespread use in over-the-counter (OTC) and prescription medications.

• BASF SE: As with Ibuprofen, BASF is a significant producer of Diphenhydramine Citrate API, leveraging its chemical manufacturing expertise and robust quality systems.

  • API Portfolio: Diphenhydramine Citrate is part of BASF's broader pharmaceutical API offerings.
  • Global Supply Network: Utilizes its established global supply chain to serve pharmaceutical manufacturers worldwide.
  • Quality Assurance: Maintains stringent quality control protocols to meet pharmaceutical industry standards.

• Anqiu Kingway Chemical Co., Ltd.: A Chinese manufacturer that produces a range of pharmaceutical intermediates and APIs, including Diphenhydramine Citrate.

  • Specialization: Focuses on specific therapeutic categories, including antihistamines.
  • Export Markets: Supplies its API to international markets, requiring compliance with various national regulatory requirements.
  • Production Volume: Operates facilities capable of producing commercial quantities of Diphenhydramine Citrate.

• Hebei Tianye Pharmaceutical Co., Ltd.: Another Chinese entity involved in the production of pharmaceutical raw materials and APIs.

  • Product Range: Includes Diphenhydramine Citrate among its offerings.
  • Manufacturing Standards: Aims to meet international quality standards for API production.
  • Competitive Pricing: Chinese manufacturers often offer competitive pricing structures.

• Jiangsu Rayiwell Pharmaceutical Co., Ltd.: A pharmaceutical company based in China that manufactures and exports various APIs.

  • API Focus: Diphenhydramine Citrate is a key product in its API portfolio.
  • International Trade: Engages in export activities, necessitating adherence to global regulatory expectations.
  • Production Capabilities: Possesses the manufacturing infrastructure to produce pharmaceutical-grade Diphenhydramine Citrate.

• Other Potential Suppliers: The market for Diphenhydramine Citrate API may include a broader set of regional manufacturers in India, Europe, and North America, though often with smaller capacities or niche market focuses compared to the larger global players.

What are the Regulatory Considerations for API Suppliers?

Suppliers of Ibuprofen and Diphenhydramine Citrate API must adhere to rigorous regulatory standards to ensure product safety, efficacy, and quality. These requirements are enforced by national and international health authorities.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines as established by regulatory bodies. For APIs, the primary guidance is typically ICH Q7.

  • Key Elements: GMP covers aspects such as facility design and maintenance, equipment qualification and calibration, raw material control, process validation, quality control testing, documentation, and personnel training.
  • Inspections: Manufacturing sites are subject to regular inspections by regulatory agencies (e.g., FDA, EMA) to verify GMP compliance.

• Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory authorities like the FDA.

  • Purpose: A DMF contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
  • Submission: Allows drug product manufacturers to reference the API information in their drug applications without having direct access to the proprietary details.
  • Types: The U.S. FDA has Type II DMFs for drug substance (API) information.

• Certificate of Suitability (CEP) / Certificate of Suitability to the Monographs of the European Pharmacopoeia (COS): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

  • Function: Demonstrates that an API complies with the requirements of the relevant European Pharmacopoeia monograph.
  • Recognition: Facilitates market access for APIs within Europe and other countries that recognize CEPs.

• Pharmacopoeia Compliance: APIs must meet the purity and quality specifications outlined in relevant pharmacopoeias.

  • Major Pharmacopoeias: United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP).
  • Testing: Manufacturers must perform and document testing against these standards.

• Impurity Profiling and Control: Regulatory bodies are increasingly focused on the control of impurities in APIs.

  • Genotoxic Impurities: Specific attention is paid to potentially genotoxic impurities, which require rigorous control strategies.
  • ICH Guidelines: ICH M7 (Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk) is a critical guideline.

• Supply Chain Security and Traceability: Ensuring the integrity and traceability of APIs from the manufacturer to the final drug product is essential.

  • Counterfeit Prevention: Measures are in place to prevent the introduction of counterfeit or substandard APIs into the supply chain.
  • Audits: Pharmaceutical companies conduct audits of their API suppliers to ensure compliance with quality and regulatory standards.

What are the Geographical Strengths of API Production?

The manufacturing landscape for Ibuprofen and Diphenhydramine Citrate APIs exhibits distinct geographical concentrations, each with its own advantages and challenges.

Asia (Primarily China and India)

• Dominant Players: China and India are the largest producers of APIs globally, including Ibuprofen and Diphenhydramine Citrate.
  • China: Home to a vast number of chemical and pharmaceutical manufacturers, offering a broad range of APIs. Production is often characterized by large scale and competitive pricing.
  • India: A well-established hub for generic drug and API manufacturing, with a strong regulatory compliance infrastructure and a significant export market. Indian companies are often strong in R&D and process optimization.
• Advantages:
  • Cost Competitiveness: Lower manufacturing costs, including labor and raw materials, contribute to competitive pricing.
  • Large Scale Production: Facilities are designed for high-volume output to meet global demand.
  • Extensive Raw Material Access: Proximity to raw material sources can streamline production.
• Challenges:
  • Regulatory Scrutiny: While improving, some facilities may face ongoing scrutiny from Western regulatory agencies regarding GMP compliance and environmental standards.
  • Supply Chain Volatility: Geopolitical factors, environmental regulations, and pandemic-related disruptions can impact supply stability.
  • Quality Consistency: While many suppliers are high-quality, due diligence is critical to identify consistently compliant manufacturers.

Europe

• Key Manufacturers: Countries like Germany and Switzerland host major multinational chemical and pharmaceutical companies with significant API production capabilities.
  • Example: BASF SE operates substantial API manufacturing sites within Europe.
• Advantages:
  • High Quality Standards: European manufacturers are known for adhering to stringent GMP and quality control protocols, often exceeding minimum requirements.
  • Regulatory Expertise: Deep understanding and proactive engagement with EMA and other European regulatory bodies.
  • Supply Chain Reliability: Generally perceived as more stable and reliable due to robust infrastructure and governance.
• Challenges:
  • Higher Manufacturing Costs: Labor, energy, and regulatory compliance costs are typically higher than in Asia.
  • Specialized Production: Focus may be on higher-value or niche APIs, with less emphasis on commoditized high-volume APIs unless integrated into a larger company's portfolio.

North America (United States)

• API Production: While API manufacturing has seen a shift to Asia, some specialized API production, including for certain high-value or sensitive compounds, still exists in the U.S. SI Group is an example of a U.S.-based producer.
  • Focus: Often involves complex synthesis, specialty chemicals, or companies prioritizing domestic supply chains.
• Advantages:
  • Proximity to Major Markets: Reduced lead times and easier logistics for North American drug product manufacturers.
  • Strong Regulatory Environment: Adherence to FDA standards is inherent.
  • Intellectual Property Protection: A more robust IP protection framework.
• Challenges:
  • Cost Disadvantage: Significantly higher manufacturing costs compared to Asian and, in some cases, European competitors.
  • Limited Scale for Commodity APIs: Less competitive for high-volume, lower-margin APIs like Ibuprofen.

What are the Critical Supply Chain Risks and Mitigation Strategies?

The global supply of Ibuprofen and Diphenhydramine Citrate APIs is susceptible to various risks that can disrupt production and impact drug availability. Proactive risk management is essential for pharmaceutical companies.

Identified Risks:

• Single-Source Dependency: Reliance on a single manufacturer for an API.
  • Impact: Any production disruption, quality issue, or geopolitical event affecting that sole supplier can lead to stock-outs.
• Geopolitical Instability and Trade Barriers: Conflicts, sanctions, tariffs, or export restrictions in key manufacturing regions.
  • Impact: Can halt or significantly delay the movement of APIs, increasing costs and lead times.
• Regulatory Non-Compliance: A supplier failing to meet GMP or other regulatory standards.
  • Impact: Can result in product recalls, import bans, and costly remediation efforts.
• Raw Material Shortages: Disruptions in the supply of key starting materials or intermediates needed for API synthesis.
  • Impact: Can halt API production even if the API manufacturer is operational.
• Logistics and Transportation Disruptions: Port congestion, shipping container shortages, or natural disasters impacting global shipping.
  • Impact: Delays in delivery, increased freight costs, and potential API degradation if temperature control is compromised.
• Quality Control Failures: Batch failures due to contamination, process deviations, or analytical errors.
  • Impact: Leads to rejected batches, production delays, and potential damage to the reputation of both the supplier and the drug product manufacturer.
• Intellectual Property Issues: Disputes related to patents or trade secrets, particularly concerning newer synthesis routes.
  • Impact: Can lead to injunctions, costly litigation, and supply interruptions.
• Environmental Regulations: Stricter environmental controls in manufacturing regions can lead to temporary or permanent plant shutdowns.
  • Impact: Reduces overall market supply and can lead to price increases.

Mitigation Strategies:

• Dual Sourcing and Multi-Sourcing: Identify and qualify at least two, preferably three, independent suppliers for critical APIs.
  • Benefit: Distributes risk across multiple manufacturers and geographical locations.
• Geographical Diversification of Suppliers: Ensure that qualified suppliers are located in different geographical regions with distinct risk profiles (e.g., one in India, one in Europe).
  • Benefit: Mitigates risks associated with regional instability or single-country regulatory actions.
• Robust Supplier Qualification and Auditing Program: Conduct thorough due diligence, including on-site audits, to verify GMP compliance, quality systems, financial stability, and ethical practices.
  • Benefit: Proactively identifies potential risks before they impact the supply chain.
• Strategic Inventory Management: Maintain appropriate safety stock levels of APIs at the drug product manufacturing sites and/or through third-party logistics providers.
  • Benefit: Provides a buffer against short-term supply disruptions.
• Contractual Safeguards: Negotiate strong supply agreements that include provisions for lead times, quality specifications, change control, business continuity, and force majeure events.
  • Benefit: Establishes clear expectations and legal recourse in case of supplier non-performance.
• Continuous Monitoring of the Supply Chain Landscape: Stay informed about geopolitical developments, regulatory changes, and market trends that could impact API supply.
  • Benefit: Enables proactive adjustments to sourcing strategies.
• Collaborative Relationships with Suppliers: Foster open communication and collaboration with key suppliers.
  • Benefit: Promotes transparency and allows for early identification of potential issues.
• Investment in Backward Integration or Key Intermediate Suppliers: For highly critical APIs, consider ensuring secure supply of key intermediates or, in rare cases, exploring backward integration strategies.
  • Benefit: Provides greater control over the entire value chain.
• Regulatory Intelligence: Actively monitor regulatory updates from agencies like the FDA, EMA, and others relevant to API manufacturing and quality.
  • Benefit: Ensures ongoing compliance and helps anticipate future regulatory demands.

Key Takeaways

The supply chain for Ibuprofen and Diphenhydramine Citrate APIs is characterized by globalized manufacturing, with significant production capacity concentrated in Asia (China and India) and established players in Europe. Key suppliers like BASF SE, SI Group, Granules India Limited, and IOL Chemicals and Pharmaceuticals Ltd. dominate the Ibuprofen market, while BASF, Anqiu Kingway Chemical, and Jiangsu Rayiwell Pharmaceutical are prominent for Diphenhydramine Citrate. Regulatory compliance, particularly adherence to GMP (ICH Q7), is non-negotiable, with DMFs and CEPs serving as critical validation tools. Supply chain risks, including single-source dependency, geopolitical instability, and quality failures, necessitate proactive mitigation through dual/multi-sourcing, geographical diversification, robust supplier qualification, and strategic inventory management. Pharmaceutical companies must maintain vigilance in monitoring market dynamics and regulatory landscapes to ensure a stable and secure supply of these essential APIs.

Frequently Asked Questions

1. How does the FDA's recent focus on impurity control impact the sourcing of Ibuprofen and Diphenhydramine Citrate APIs?

The FDA's intensified scrutiny on impurities, especially potentially genotoxic ones, means API suppliers must demonstrate robust impurity profiling and control strategies aligned with ICH M7. Manufacturers must provide detailed data in their Drug Master Files (DMFs) proving their control over these impurities, potentially leading to stricter qualification requirements for new suppliers and increased analytical testing for existing ones.

2. Are there significant price differences between API suppliers in China, India, and Europe for Ibuprofen and Diphenhydramine Citrate?

Generally, suppliers in China and India tend to offer more competitive pricing due to lower manufacturing and labor costs. European suppliers, while often commanding higher prices, may offer advantages in terms of established quality systems, regulatory assurance, and supply chain reliability, which can offset initial cost differences for certain pharmaceutical manufacturers.

3. What is the typical lead time for ordering large commercial quantities of these APIs from major global suppliers?

Typical lead times for large commercial orders of Ibuprofen and Diphenhydramine Citrate APIs can range from 3 to 6 months. This duration accounts for production scheduling, quality control testing, documentation, and global shipping. However, lead times can fluctuate based on supplier capacity, raw material availability, and current global logistics conditions.

4. How can a pharmaceutical company assess the long-term viability and stability of an API supplier in Asia?

Assessing long-term viability involves a multi-faceted approach. Key metrics include the supplier's financial health, their investment in R&D and capacity expansion, their history of regulatory compliance (e.g., FDA/EMA inspection outcomes), their diversification of customer base, and their commitment to environmental sustainability. Regular supplier audits and continuous market intelligence are crucial.

5. What are the implications of API manufacturing moving back to Western countries ("reshoring") for the supply of Ibuprofen and Diphenhydramine Citrate?

While there is a trend towards exploring reshoring for certain critical medicines, the high-volume, cost-sensitive nature of Ibuprofen and Diphenhydramine Citrate APIs makes a complete shift back to Western countries unlikely in the short to medium term. Reshoring efforts may focus on APIs with significant national security implications or complex manufacturing requirements. For these specific APIs, the primary impact may be increased geopolitical pressure on established Asian supply chains, potentially leading to diversification strategies rather than a wholesale relocation of manufacturing.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/guidances-agreements-pharmaceutical-companies/drug-master-files-dmfs [2] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-monographs-european-pharmacopoeia-cep [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Q7_Step_4.pdf [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/M7/Step_4/M7_Guideline.pdf [5] Granules India Limited. (Investor Presentations & Annual Reports, various years). [Information accessed through company's investor relations portal and public filings]. [6] IOL Chemicals and Pharmaceuticals Ltd. (Investor Presentations & Annual Reports, various years). [Information accessed through company's investor relations portal and public filings]. [7] BASF SE. (Product Information & Corporate Publications, various years). [Information accessed through BASF's official website and relevant industry publications]. [8] SI Group. (Product Information & Corporate Publications, various years). [Information accessed through SI Group's official website and relevant industry publications]. [9] Anqiu Kingway Chemical Co., Ltd. (Product Catalog & Company Information, various years). [Information accessed through company's official website and trade portals]. [10] Jiangsu Rayiwell Pharmaceutical Co., Ltd. (Product Catalog & Company Information, various years). [Information accessed through company's official website and trade portals].